Insulin analogues: An example of applied medical science

Diabetes, Obesity and Metabolism

Volumn 11, Issue 1, 2009, Pages 5-19

  Sheldon, Benjamin ^a   Russell Jones, D ^a   Wright, J ^a  

^a UNIVERSITY OF SURREY   (United Kingdom)

Author keywords

Aspart; Detemir; Glargine; Glulisine; Insulin analogue; Lispro

Indexed keywords

BIPHASIC INSULIN; FATTY ACID; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; INSULIN; INSULIN ASPART; INSULIN DERIVATIVE; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN GLULISINE; INSULIN LISPRO; ISOPHANE INSULIN; ORAL ANTIDIABETIC AGENT;

AMINO ACID SEQUENCE; BIOEQUIVALENCE; CLINICAL TRIAL; CONTINUOUS INFUSION; DRUG ABSORPTION; DRUG BINDING; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; GLUCOSE BLOOD LEVEL; GLUCOSE CLAMP TECHNIQUE; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN PUMP; INSULIN TREATMENT; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT SATISFACTION; PHARMACODYNAMICS; PREGNANCY; QUALITY OF LIFE; REVIEW; SIDE EFFECT; WEIGHT GAIN;

EID: 58149201128     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2008.01015.x     Document Type: Review

References (103)

1. Bliss M. The Discovery of Insulin. University of Chicago Press, Chicago, Illinois, USA. 1982.
2. Roscamp RH, Park G. Long acting analogues. Diabetes Care 1999; 22: S2B109-S2B113.
3. Hagedorn HC, Jensen BN, Krarup NB. Wodstrug I Protamine insulinate. J Am Med Assoc 1936; 106: 177-180.
4. Hallas-Moller K. The lente insulins. Diabetes 1956; 5: 7-14.
5. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Eng J Med 1993; 329: 977-986.
6. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853. (Erratum, Lancet 1999; 354: 602).
7. Ryle AP, Sanger F, Smith LF, Kitai R. The disulphide bonds of insulin. Biochem J 1955; 60: 541-556.
8. Hodgkin DC. The Banting Memorial Lecture. The structure of insulin. Diabetes 1972; 1972: 1131-1150.
9. Yalow RS, Berson SA. Immunoassay of endogenous plasma insulin in man. J Clin Invest 1960; 39: 1157-1175.
10. De Meyts P, Van Obberghen E, Roth J, Brandenburg D, Wollmer A. Mapping of the residues responsible for the negative co-operativity of the receptor binding region of insulin. Nature 1978; 273: 504.
11. Shojaee-Moradie F, Powrie JK, Sundermann E et al. Novel hepatoselective insulin analog: Studies with a covalently linked thyroxyl-insulin complex in humans. Diabetes Care 2000; 23: 1124-1129.
12. Slieker LJ, Brooke GS, DiMarchi RD et al. Modifications in the B10 and B26-30 regions of the B chain of human insulin alter affinity for the human IGF-I receptor more than for the insulin receptor. Diabetologia 1997; 40: S54-S61.
13. Kurtzhals P, Schaffer L, Sorensen A et al. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes 2000; 49: 999-1005.
14. Vajo Z, Fawcett J, Duckworth W. Recombinant DNA technology in the treatment of diabetes: Insulin analogs. Endocr Rev 1994; 22: 706-717.
15. Howey DC, Bowsher RR, Brunelle RL, Woodworth JR. [Lys(B28),Pro(B29)]-human insulin: A rapidly absorbed analogue of human insulin. Diabetes 1994; 43: 396-402.
16. Torlone E, Fanelli C, Rambotti AM et al. Pharmacokinetics, pharmacodynamics and glucose counterregulation following subcutaneous injection of the monomeric insulin analogue [Lys(B28),Pro(B29)] in IDDM. Diabetologia 1994; 37: 713-720.
17. Mudaliar SR, Lindberg FA, Joyce M et al. Insulin aspart (B28 asp-insulin): A fast-acting analoA of human insulin: absorption kinetics and action profile compared with regular human insulin in healthy nondiabetic subjects. Diabetes Care 1999; 22: 1501-1506.
18. Garg SK, Ellis SL, Ulrich H. Insulin glulisine: A new rapid-acting insulin analogue for the treatment of diabetes. Expert Opin Pharmacother 2005; 6: 643-651.
19. Becker RH, Frick AD, Burger F et al. A comparison of the steady-state pharmacokinetics and pharmacodynamics of a novel rapid-acting insulin analog, insulin glulisine, and regular human insulin in healthy volunteers using the euglycemic clamp technique. Exp Clin Endocrinol Diabetes 2005; 113: 292-297.
20. Pfutzner A, Kustner E, Forst T et al. Intensive insulin therapy with insulin lispro in patients with type 1 diabetes reduces the frequency of hypoglycemic episodes. Exp Clin Endocrinol Diabetes 1996; 104: 25-30.
21. Anderson JH Jr, Brunelle RL, Koivisto VA et al. Reduction of postprandial hyperglycemia and frequency of hypoglycemia in IDDM patients on insulin-analog treatment. Multicenter Insulin Lispro Study Group. Diabetes 1997; 46: 265-270.
22. Brunelle BL, Llewelyn J, Anderson JH Jr, Gale EA, Koivisto VA. Meta-analysis of the effect of insulin lispro on severe hypoglycemia in patients with type 1 diabetes. Diabetes Care 1998; 21: 1726-1731.
23. Raskin P, Guthrie RA, Leiter L, Riis A, Jovanovic L. Use of insulin aspart, a fast-acting insulin analog, as the mealtime insulin in the management of patients with type 1 diabetes. Diabetes Care 2000; 23: 583-588.
24. Brunner GA, Hirschberger S, Sendlhofer G et al. Post-prandial administration of the insulin analogue insulin aspart in patients with type 1 diabetes mellitus. Diabet Med 2000; 17: 371-375.
25. Home PD, Lindholm A, Hylleberg B, Round P. Improved glycemic control with insulin aspart: A multicenter randomized double-blind crossover trial in type 1 diabetic patients. UK Insulin Aspart Study Group. Diabetes Care 1998; 21: 1904-1909.
26. Gale EA. A randomised, controlled trial comparing insulin lispro with human soluble insulin in patients with type 1 diabetes on intensified insulin therapy. The UK Trial Group. Diabet Med 2000; 17: 209-214.
27. Siebenhofer A, Plank J, Berghold A et al. Short acting insulin analogues versus regular human insulin in patients with diabetes mellitus. Cochrane Database Syst Rev 2006.
28. Chapman TM, Noble S, Goa KL. Insulin aspart: A review of its use in the management of type 1 and 2 diabetes mellitus. Drugs 2002; 62: 1945-1981.
29. Heller S. Reducing hypoglycaemia with insulin analogues. Int J Obes Relat Metab Disord 2002; 26(Suppl. 3): S31-S36.
30. Dreyer M, Prager R, Robinson A, et al. Efficacy and safety of insulin glulisine and insulin lispro combined with insulin glargine in patients with type 1 diabetes. Diabetes 2004; 53(Suppl. 2).
31. Bott U, Ebrahim S, Hirschberger S, Skovlund SE. Effect of the rapid-acting insulin analogue insulin aspart on quality of life and treatment satisfaction in patients with type 1 diabetes. Diabet Med 2003; 20: 626-634.
32. DeWitt DE, Hirsch IB. Outpatient insulin therapy in type 1 and type 2 diabetes mellitus: Scientific review. JAMA 2003; 289: 2254-2264.
33. Farmer AJ, Thorne KA, Stratton IM et al. Treating to target in type 2 diabetes (4-T) study of analogue insulin initiation and titration. Diabet Med 2006; 23(Suppl. 2): 85.
34. Rosenstock J, Ahmann AJ, Colon G, Scism-Bacon J, Jiang H, Martin S. Advancing insulin therapy in type 2 diabetes previously treated with glargine plus oral agents: Prandial premixed (insulin lispro protamine suspension/lispro) versus basal/bolus (glargine/lispro) therapy. Diabetes Care 2008; 31: 20-25.
35. Anderson JH Jr, Brunelle RL, Keohane P et al. Mealtime treatment with insulin analog improves postprandial hyperglycemia and hypoglycemia in patients with non-insulin-dependent diabetes mellitus. Multicenter Insulin Lispro Study Group. Arch Intern Med 1997; 157: 1249-1255.
36. Dailey G, Rosenstock J, Moses RG, Ways K. Insulin glulisine provides improved glycemic control in patients with type 2 diabetes. Diabetes Care 2004; 27: 2363-2368.
37. Mannucci E, Monami M, Marchionni N. Short-acting insulin analogues vs. regular human insulin in type 2 diabetes: A meta-analysis. Diabetes Obes Metab 2008 [Epub 30 July 2008].
38. Bode B, Weinstein R, Bell D et al. Comparison of insulin aspart with buffered regular insulin and insulin lispro in continuous subcutaneous insulin infusion: A randomized study in type 1 diabetes. Diabetes Care 2002; 25: 439-444.
39. Weinzimer SA, Ternand C, Howard C et al. A randomized trial comparing continuous subcutaneous insulin infusion of insulin aspart versus insulin lispro in children and adolescents with type 1 diabetes. Diabetes Care 2008; 31: 210-215.
40. Bode BW. Use of rapid-acting insulin analogues in the treatment of patients with type 1 and type 2 diabetes mellitus: Insulin pump therapy versus multiple daily injections. Clin Ther 2007; 29(Suppl. D): S135-S144.
41. Hoogma RP, Schumicki D. Safety of insulin glulisine when given by continuous subcutaneous infusion using an external pump in patients with type 1 diabetes. Horm Metab Res 2006; 38: 429-433.
42. Miles HL, Acerini CL. Insulin analog preparations and their use in children and adolescents with type 1 diabetes mellitus: Review article. Pediatr Drugs 2008; 10: 163-176.
43. Danne T. Flexibility of rapid-acting insulin analogues in children and adolescents with diabetes mellitus. Clin Ther 2007; 29(Suppl. D): S145-S152.
44. Danne T, Aman J, Schober E et al. A comparison of postprandial and preprandial administration of insulin aspart in children and adolescents with type 1 diabetes. Diabetes Care 2003; 26: 2359-64.
45. Durnwald CP, Landon MB. A comparison of lispro and regular insulin for the management of type 1 and type 2 diabetes in pregnancy. J Matern Fetal Neonatal Med 2008; 21: 309-313.
46. Hod M, Damm P, Kaaja R et al. Fetal and perinatal outcomes in type 1 diabetes pregnancy: A randomized study comparing insulin aspart with human insulin in 322 subjects. Am J Obstet Gynaecol 2008; 198: 186.e1-187.e1.
47. Hermansen K, Fontaine P, Kukolja KK et al. Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes. Diabetologia 2004; 47: 622-629.
48. Garber AJ, Ligthelm R, Christiansen JS, Liebl A. Premixed insulin treatment for type 2 diabetes: Analogue or human? Diabetes Obes Metab 2007; 9: 630-639.
49. Ilag LL, Kerr L, Malone JK, Tan MH. Prandial premixed insulin analogue regimens versus basal insulin analogue regimens in the management of type 2 diabetes: An evidence-based comparison. Clin Ther 2007; 29 Spec No: 1254-1270.
50. Rossetti P, Porcellati F, Fanelli C et al. Superiority of insulin analogues versus human insulin in the treatment of diabetes mellitus. Arch Physiol Biochem 2008; 114: 3-10.
51. Raja-Khan N, Warehime S, Gabbay R. Review of biphasic insulin aspart in the treatment of type 1 and 2 diabetes. Vasc Health Risk Manag 2007; 3: 919-935.
52. Raskin PR, Allen E, Hollander P et al. Initiating insulin therapy in type 2 diabetes. Diabetes Care 2005; 28: 260-265.
53. Garber A, Wahlen J, Wahl T et al. Attainment of glycaemic goals in type 2 diabetes with once, twice or thrice daily dosing with biphasic insulin aspart 70/30 The 1-2-3 study. Diabetes Obes Metab 2005; 7: 73-82.
54. Ligthelm RJ, Mouritzen U, Lynggaard H et al. Biphasic insulin aspart given thrice daily is as efficacious as a basal-bolus insulin regimen with four daily injections: A randomized open-label parallel group four months comparison in patients with type 2 diabetes. Exp Clin Endocrinol Diab 2006; 114: 511-519.
55. Iwamoto Y. A randomized, multicentre trial of biphasic insulin aspart versus biphasic human insulin in type 2 diabetes. Diabetologia 2003; 46(Suppl. 2): A270.
56. Hermansen K, Colombo M, Storgarrd H et al. Improved postprandial glycemic control with biphasic insulin aspart relative to biphasic insulin lispro and biphasic human insulin in patients with type 2 diabetes. Diabetes Care 2002; 25: 883-888.
57. Bolli GB, Owens DR. Insulin glargine (commentary). Lancet 2000; 356: 443-445.
58. Heise T, Bott S, Rave K, Dressler A, Rosskamp R, Heinemann L. No evidence for accumulation of insulin glargine (Lantus): A multiple injection study in patients with type 1 diabetes. Diabetes Med 2002; 19: 490-495.
59. Lepore M, Pampanelli S, Fanelli C et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 2000; 49: 2142-2148.
60. Havelund S, Plum A, Ribel U et al. The mechanism of protraction of insulin detemir: A long-acting, acylated analog of human insulin. Pharm Res 2004; 21: 1498-1504.
61. Kurtzhals P, Havelund S, Jonassen I, Markussen J. Effect of fatty acids and selected drugs on the albumin binding of a long-acting acylated insulin analogue. J Pharm Sci 1997; 86: 1365-1368.
62. Kurtzhals P. Engineering predictability and protraction in a basal insulin analogue; the pharmacology of insulin detemir. Int J Obes 2004; 28(Suppl. 2): S23-S28.
63. Kurtzhals P. Pharmacology of insulin detemir (Levemir). Endocrinol Metab Clin N Am 2007; 36 (Suppl.): 14-20.
64. Hordern SV, Wright JE, Umpleby AM et al. Comparison of the effects on glucose and lipid metabolism of equipotent doses of insulin detemir and NPH insulin with a 16-h euglycaemic clamp. Diabetologia 2005; 48: 420-426.
65. Heise T, Pieber TR. Towards peakless, reproducible and long-acting insulins. An assessment of the basal analogues based on isoglycaemic clamp studies. Diabetes Obes Metab 2007; 9: 648-659.
66. Heise T, Nosek L, Ronn BB et al. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes 2004; 53: 1614-1620.
67. Klein O, Lynge J, Endahl L et al. Albumin-bound basal insulin analogues (insulin detemir and NN344): Comparable time-action profiles but less variability than insulin glargine in type 2 diabetes. Diabetes Obes Metab 2007; 9: 290-299.
68. Rossetti P, Pampanelli S, Fanelli C et al. Intensive replacement of basal insulin in patients with type 1 diabetes given rapid-acting insulin analog at mealtimes: A three month comparison between administration of NPH insulin four time daily and glargine insulin at dinner or bedtime. Diabetes Care 2003; 26: 1490-1496.
69. Ratner RE, Hirsch IB, Neifing JL, Garg SK, Mecca TE, Wilson CA. Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. Diabetes Care 2000; 23: 639-643.
70. Raskin P, Klaff L, Bergenstal R, Halle JP, Donley D, Mecca T. A 16-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with type 1 diabetes. Diabetes Care 2000; 23: 1666-1671.
71. Yki-Jarvinen H, Dressler A, Ziemen M. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. Diabetes Care 2000; 23: 1130-1136.
72. Riddle MC, Rosenstock J, Gerich J et al. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetes patients. Diabetes Care 2003; 26: 3080-3086.
73. Davies M, Storms F, Shutler S, Bianchi-Biscay M, Gomis R; Atlantus Study Group. Improvement of glycemic control in subjects with poorly controlled type 2 diabetes: Comparison of two treatments algorithms using insulin glargine. Diabetes Care 2005; 28: 1282-1288.
74. Horvath K, Jeitler K, Berghold A et al. Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus. Cochrane Database Syst Rev 2007.
75. Elisaschewitz FG, Calvo C, Valbuena H et al. Therapy in type 2 diabetes: insulin glargine vs. NPH insulin both in combination with glimepiride. Arch Med Res 2006; 37: 495-501.
76. Fritsche A, Schweitzer MA, Haring HU, Study Group. Glimepiride combined with morning insulin glargine, bedtime neutral protamine Hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. Ann Int Med 2003; 138: 952-959.
77. Fonseca V, Bell DS, Berger S, Thomson S, Mecca TE. A Comparison of bedtime insulin glargine with bedtime neutral protamine Hagedorn insulin in patients with type 2 diabetes: Subgroup analysis of patients taking once-daily insulin in a multicenter randomised, parallel group study. Am J Med Sci 2004; 328: 274-280.
78. Yki-Jarvinen H, Kauppinen-Makelin R, Tiikkainen M et al. Insulin glargine or NPH combined with metformin in type 2 diabetes: The Lanmet Study. Diabetologia 2006; 49: 442-451.
79. Massi BM, Humburg E, Dressler A, Ziemen M. A one-year, randomised, multicentre trial comparing insulin glargine with NPH insulin in combination with oral agents in patients with type 2 diabetes. Horm Metab Res 2003; 35: 189-196.
80. Home P, Bartley P, Russell-Jones D et al. Insulin detemir offers improved glycemic control compared with NPH insulin in people with type 1 diabetes: A randomised clinical trial. Diabetes Care 2004; 27: 1081-1087.
81. Pieber TR, Treichel H-C, Robertson LI et al. Insulin detemir plus insulin aspart is associated with less risk of major as well as nocturnal hypoglycaemia than insulin glargine plus insulin aspart at comparable levels of glycemic control in type 1 diabetes. Diabetologia 2005; 48: A92.
82. Russell-Jones D, Simpson R, Hylleberg B et al. Effects of QD insulin detemir or neutral protamine Hagedorn on blood glucose control in patients with type 1 diabetes mellitus using a basal-bolus regimen. Clin Ther 2004; 26: 724-36.
83. Kolendorf K, Ross GP, Pavlic-Renar I et al. Insulin detemir lowers the risk of hypoglycemia and provides more consistent plasma glucose levels compared with NPH insulin in type 1 diabetes. Diabetes Med 2006; 23: 729-735.
84. Pieber TR, Draeger E, Kristensen A, Grill V. Comparison of three multiple injection regimens for type 1 diabetes: Morning plus dinner or bedtime administration of insulin detemir vs. morning plus bedtime NPH insulin. Diabetes Med 2005; 22: 850-857.
85. Standl E, Lang H, Roberts A. The 12-month efficacy and safety of insulin detemir and NPH insulin in basal-bolus therapy for the treatment of type 1 diabetes. Diabetes Technol Ther 2004; 6: 579-588.
86. Vague P, Selam J-L, Skeie S et al. Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart. Diabetes Care 2003; 26: 590-596.
87. De Leeuw I, Vague P, Selam J-L et al. Insulin detemir used in basal-bolus therapy in people with type 1 diabetes is associated with a lower risk of nocturnal hypoglycemia and less weight gain over 12 months in comparison to NPH insulin. Diabetes Obes Metab 2005; 7: 73-82.
88. Heller S, Hansoo K. Insulin detemir reduces hypoglycaemic risk at comparable HbA1c values compared to NPH in patients with type 1 diabetes. 65th Annual Scientific Sessions of the American Diabetes Association. 10-14 June, 2005; San Diego, California.
89. Russell-Jones D, Kim H, Heller S, Clauson P. Insulin detemir reduces the risk of hypoglycemia at all levels of HbAlc compared to NPH insulin in the context of basal-bolus therapy for type 1 diabetes. Diabetologia 2005; 48: A92.
90. Hermansen K, Davies M, Derezinski T, Martinez RG, Clauson P, Home P. A 26-week, randomised, parallel, treat-to-target trial compared insulin detemir with NPH insulin as add-on-therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care 2006; 29: 1269-1274.
91. Philis-Tsimikas A, Charpentier G, Clauson P et al. Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes. Clin Ther 2006; 28: 1569-1581.
92. Haak T, Tiengo A, Draeger E, Suntum M, Waldhausl W. Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes. Diabetes Obes Metab 2005; 7: 56-64.
93. Rosenstock J, Davies M, Home PD et al. Insulin detemir added to oral anti-diabetic drugs in type 2 diabetes provides glycemic control comparable to insulin glargine with less weight gain. Diabetes 2006; 55(Suppl.): A132.
94. Chase H, Dixon B, Pearson J et al. Reduced hypoglycaemic episodes and improved glycaemic control in children with type 1 diabetes using insulin glargine and nPH insulin. J Pediatr 2003; 143: 737-40.
95. Robertson KJ, Schonle E, Gucev Z et al. Insulin detemir compared with NPH insulin in children and adolescents with type 1 diabetes. Diabet Med 2007; 24: 27-34.
96. Janka HU. Insulin therapy in elderly patients with type 2 diabetes: The role of insulin glargine. Diabetes Obes Metab 2008; 10(Suppl. 2): 35-41.
97. Kruszynska YT, Home PD, Hanning I et al. Basal and 24-h C-peptide and insulin secretion in normal man. Diabetologia 1987; 30: 16-21.
98. Brange J. Design of insulin analogues for meal-related therapy. J Diab Comp 1993; 7: 106-112.
99. Brange J, Volund A. Insulin analogs with improved pharmacokinetic profiles. Adv Drug Del Rev 1999; 35: 307-335.
100. Oiknine R, Bernbaum M, Mooradian AD. A critical appraisal of the role of insulin analogues in the management of diabetes mellitus. Drugs 2005; 65: 325-340.
101. Becker RHA, Frick AD, Kapizita CK et al. Pharmacodynamics (PD) and pharmacokinetics (PK) of insulin glulisine compared with insulin lispro (IL) and regular human insulin (RHI) in patients with type 2 diabetes [abstract no. 503-P]. Diabetes 2004; 53 (Suppl. 2): A119.
102. Seipke G, Stammberger I. Effects of insulin glulisine on the insulin and IGF-1 receptor signaling cascades. Diabetes 2005; 54 (Suppl. 1): A339-A340.
103. Lindholm A. New insulins in the treatment of diabetes mellitus. Best Practi Res Clin Gastroenterol 2002; 16: 475-492.